Trials / Active Not Recruiting
Active Not RecruitingNCT03104842
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 246 (actual)
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Isatuximab | Antibody Intravenous |
| DRUG | Carfilzomib | Intravenous |
| DRUG | Lenalidomide | Capsel |
| DRUG | Dexamethasone | Capsel |
Timeline
- Start date
- 2017-08-15
- Primary completion
- 2026-05-01
- Completion
- 2026-09-01
- First posted
- 2017-04-07
- Last updated
- 2024-05-29
Locations
17 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03104842. Inclusion in this directory is not an endorsement.